The Pharma Outsourcing Best Practices Panel
Magid Abou-Gharbia, Ph.D.
Associate Dean for Research at Temple University
Dr. Abou-Gharbia is currently the Associate Dean for Research, Professor of Medicinal Chemistry and Director of the Moulder Center for Drug Discovery Research (MCDDR) at the School of Pharmacy, Temple University, Philadelphia, PA.
He is responsible for Setting and implementing School of Pharmacy research strategies to promote the school’s research and entrepreneurial enterprise.
Prior to joining Temple University in 2008, Magid spent 26 years at Wyeth Pharmaceuticals where he was Senior Vice President and Head of Chemical and Screening Services. As Senior Vice President & Head of Chemical & Screening Sciences at Wyeth, he was responsible for overseeing and directing Wyeth worldwide chemistry and screening research efforts of 500 scientists at four US research facilities and 150 chemists in Hyderabad, India in support of drug discovery in Neuroscience, Inflammation, Women’s Health/Bone, Oncology and Cardiovascular/Metabolic Diseases therapeutic areas.
Over the years, Dr. Abou-Gharbia led research efforts in Medicinal Chemistry and Drug discovery at Wyeth which resulted in the discovery of eight marketed drugs and many compounds currently under clinical evaluation including: the first-in-class SNRI antidepressant Effexor® and Pristiq®; short-acting hypnotic Sonata® , the anticancer agent Mylotarg® the first FDA approved antibody drug conjugate; an anticancer Torisel® (temsirolimus), first FDA approved m-TOR inhibitor; a broad spectrum antibiotic Tygacil®, anticancer kinase inhibitor Bosutinib®, and a non-steroidal, estrogen modulator Viviant™, (Bazedoxifene®) which opened up new options for the treatment of postmenopausal osteoporosis.
Education: BS in Pharmacy and Pharmaceutical Sciences (1971), MS in Medicinal Chemistry (1974) from the School of Pharmacy, Cairo University, and Ph.D. (1979) from the University of Pennsylvania working with Professor Madeleine Joullie, followed by a two-year NIH Postdoctoral Fellowship at Temple University Medical School and the Department of Chemistry.
Among his recent contributions in the Middle East are the establishment of Qatar Biomedical Research Institute (QBRI), instituting medicinal chemistry and drug discovery research at four major educational institutions in the region: the University of Sharja’s School of Pharmacy in the UAE, the Misr University for Science and Technology (MUST) in Egypt, Future University in Egypt (FUE) and City of Scientific Research and Technological Applications (SERTA-City) in Egypt.
In addition, Dr. Abou-Gharbia continue to welcome and host visiting Scholars, faculty, and students in sabbaticals, internships, and Fellowships in his laboratories in an effort to further boost biomedical research in many institutions in the US and abroad through training in Life Sciences and modern drug discovery methods.
Susan B. Billings, Ph.D.
Vice President, Global Head of Business Development
Susan B. Billings, Ph.D., is Vice President and Global Head, Business Development at AMRI, and is responsible for leading the Global Chemical Development Business Development team. Dr. Billings is responsible for AMRI’s global chemical/process development, API manufacturing, key account management and strategy lead for AMRI’s chemical development franchise. She has been AMRI’s top global leader in contract sales and relationship management for 3 consecutive years which has led to significant customer relationship growth. Prior to AMRI, Dr. Billings worked as a Sourcing Operations Manager at Merck supporting the externalization of preclinical programs and began her career as a medicinal chemist at TetraLogic Pharmaceuticals. Dr. Billings received her B.S. degree in chemistry from Villanova University, followed by a doctorate in organic chemistry from the University of California, Irvine.
Associate Director, Procurement at Lilly
Rebecca Bishop is Associate Director, Procurement at Lilly where she leads a team supporting Monoclonal Antibody Manufacturing in Branchburg, NJ. She is responsible for developing and implementing the sourcing strategies for raw materials, facilities management, and capital projects at Lilly’s NJ and NY sites.
Rebecca joined Lilly in 2014 as a member of Global Procurement supporting small molecule API manufacturing at both external and internal Lilly API sites. In 2015 - 2016 she also spent time at Lilly’s Kinsale, Ireland manufacturing site supporting both small and large molecule API manufacturing.
Prior to joining Lilly she held various roles of increasing responsibilities with Cambridge Major Laboratories and Cedarburg Hauser Pharmaceuticals. Rebecca earned a Master’s degree in Biology with focus on Evolutionary Genetics from Bowling Green State University and an MBA from Cardinal Stritch University, she also holds a Bachelor’s degree in Biology from the University of Findlay.
Nicola Giubellina, Ph.D.
Head of CRAMS Sales at Dishman Carbogen Amcis Ltd.
Nicola holds an MBA degree in International Management and a PhD in chemical synthesis.
He has over 15 years of industry experience as a sales director and in project management for CMO and Pharma companies, with a short tenure as a research associate at University of Ghent (Belgium).
Nicola currently leads the sales activities of Customer Research And Manufacturing Services (CRAMS) for Dishman Carbogen Amcis, a leading provider of custom manufacturing solutions for pharmaceutical companies. Over the past three years, he has implemented successful strategies that have driven business growth in Europe and the United States, with the acquisition of new customers and the growth of existing accounts.
Rudolf Hanko, Ph.D.
CEO at Siegfried
On May 1, 2009, Dr. Rudolf Hanko (1955) took over as CEO of Siegfried.
Prior to Siegfried, he worked in the chemical-pharmaceutical industry in various management positions, most recently with Evonik Industries AG, a German company, as head of Custom Synthesis and Amino Acids division.
Rudolf Hanko also headed the Pharmaceutical division of Bayer AG as head of Chemical Research and as General Manager of the Fine Chemicals division.
Rudolf Hanko received his Ph.D. in Chemistry from the University of Goettingen, Germany.
Syed T. Husain
Chief Commercial Officer at Alcami
Syed T. Husain is Alcami’s Chief Commercial Officer and the driving force behind the organization’s thriving commercial strategy, pioneering innovative customer experience solutions leading to strong portfolio diversity and business growth. Husain has over 15 years of leadership experience in business development, sales, marketing, and operational roles within the contract development and manufacturing (CDMO) industry across drug substance and drug product. Previously, Husain served as Head of Lonza’s Chemical API Manufacturing Business, where he was instrumental in the commercial strategy development for small molecules, antibody drug conjugates, and peptides. His prior industry expertise includes increasing roles of commercial responsibility as Lonza’s Director of Sales & Business Development and Head of Sales & Business Development responsible for Biologic and Chemical APIs. In November 2017, Husain was appointed to the Drug, Chemical and Associated Technologies Association (DCAT) Advisory Council, where he will provide insight and guidance to the Board of Directors, industry committees and task forces. Syed holds a Bachelor’s of Science in Chemical Engineering from the New Jersey Institute of Technology and an MBA from Cornell University.
Prashant S. Savle, Ph.D.
Director, Commercialization Projects, Global Procurement at Merck & Co.
S. Savle, Ph.D., Director, Commercialization Projects, Global Procurement at Merck & Co. has over 20 years of technical, business, and program management, including global experience in technology development and scale up, R&D and clinical API sourcing, process validation and commercial contract management. He brings a unique blend of experience from buyer side sourcing and also as a project manager with large contract manufacturing organizations such as Rhodia ChiRex , Avecia Biotechnology, Inc. and Sigma-Aldrich Fine Chemicals. Prashant has supported drug substance manufacturing projects spanning small molecules, antibiotics, bioconjugates, peptides and oligonucleotides, and has been a part of launch teams that have obtained 23 New Drug Approvals to date. His current responsibilities include commercialization of drug substance and non-sterile drug product formulations. Prashant has been a recipient of Ph.D. in Organic Chemistry from University of Cambridge, U.K.
Vice President, Innovator Products & Solutions at Johnson Matthey
Nicholas Shackley has over twenty years’ experience in the Pharmaceutical Fine Chemical sector in various Commercial and General Management roles.
Nick currently leads Johnson Matthey’s Contract & Development Manufacturing Services business as its Vice President, Innovator Products & Solutions. Nick has previously held the position of Senior Vice President at Aceto Corporation where he was responsible for the pharmaceutical ingredients businesses. Prior to this, Nick has had senior positions at BASF, Cambrex and Zeneca and holds a BEng from Imperial College, London.
Executive VP Global Business Development at Siegfried
Marianne Spaene (1962), Head of Business Development & Sales since March 1, 2010, was appointed President of the former Generics Division of Siegfried Ltd. in October 2008. Since January 2008, she was responsible for the Classical Generics business unit. Between June 2004 and January 2008, Marianne Spaene was in charge of Business Development and Supply Chain Management for generic drugs.
Before joining Siegfried, she held positions as Logistics, Business Development and Site Manager for the cosmetics division of Boucheron. She later switched to the pharmaceutical industry as Head of Sales and Marketing in the Pharma Division of Schweizerhall and the American Aceto Company, focusing on expansion strategies for Europe. She has degrees in Finance, Economics and Marketing from the Kaufmännische Führungsschule (KFS) Basel and the Marketing & Business School Zurich (MBSZ).
Robert Waltermire, Ph.D.
Vice President, Head Chemical & Synthetic Development, Global Product Development & Supply at Bristol Myers Squibb
Robert Waltermire is currently Vice President, Head Chemical & Synthetic Development at The Bristol-Myers Squibb Company. In this role, Rob leads a global team of approximately 300 scientists and engineers responsible for the design and development of synthetic routes, processes and all analytical methodologies for small molecule and millamolecule drug candidates. The team utilizes the fundamentals of analytical chemistry, chemical engineering and organic chemistry, modelling and simulation, real time analytics, and high throughput laboratory automation screening tools to deliver well characterized processes for the efficient synthesis of millamloecular and small molecule drug candidates.
Rob received his undergraduate training in chemistry at Franklin and Marshall College where he worked for two years under the direction of Professor William Tamblyn on applications of Organometallic reagents to Organic Synthesis. His graduate training in Organic Chemistry was performed under the direction of Professor Philip DeShong at The Pennsylvania State University and the University of Maryland.
Rob has authored 20 publications and 2 invited book chapters and is named as an inventor on 8 patents.